Abstract
Dyslipidaemia is an important risk factor in the development of atherosclerotic cardiovascular disease in people with diabetes. This article discusses the lipid modifying therapies available, and the current evidence and guidance on their use in diabetes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have